The enhancement of the therapeutic window (TW) in oncology remains a significant challenge, as the majority of anticancer treatments face difficulties in achieving optimal tumor control while minimizing adverse effects. Traditional chemotherapeutic agents, while demonstrating efficacy, are constrained by their limited TWs and the occurrence of systemic adverse effects.
Objective:
Recent advancements in precision medicine have revolutionized this paradigm by facilitating targeted tumor intervention via molecularly guided therapies, immuno-oncology strategies, and biomarker-driven patient classification. Novel approaches, including nanomedicine, antibody–drug conjugates, and prodrug formulations, improve therapeutic selectivity through the optimization of drug delivery, biodistribution, and release kinetics.
Methodology:
The concurrent advancements in radiotherapy, adaptive dosing methodologies, and toxicity assessment instruments have expanded the potential to enhance treatment intensity while preserving the integrity of normal tissues. In the future, the convergence of artificial intelligence (AI), multiomics profiling, and systems biology is anticipated to enhance therapeutic decision-making and expedite the creation of more personalized and adaptive interventions.
Results:
The efficacy of cancer treatments is substantially limited by notable shortcomings in research, despite progress in precision oncology. Tumor heterogeneity, the emergence of resistance mechanisms, and the absence of reliable biomarkers for anticipating treatment outcomes present significant impediments. The utilization of multiomics data and AI in clinical decision-making remains in its early stages, constrained by limitations in data validation and standardization. Furthermore, the translation of transdisciplinary concepts into accessible treatments is crucial, especially in environments with limited resources. Consequently, addressing these multifaceted issues is essential for improving the efficacy and safety of cancer treatments.
Conclusion:
This review integrates contemporary strategies and examines prospective pathways for expanding the TW, highlighting the intersection of technology, biology, and clinical innovation in the progression of cancer treatment.
ChenC, LiuX, ChangCY, et al.The interplay between T cells and cancer: The basis of immunotherapy. Genes (Basel)2023;14(5):1008.
2.
ZhangL, SunL, ZhouY, et al.Association of survival and immune-related adverse events with anti-PD-1/PD-L1 and anti-CTLA-4 inhibitors, alone or their combination for the treatment of cancer: A systematic review and meta-analysis of 13 clinical trials. Front Oncol2021;11:575457.
3.
KlößS, DehmelS, BraunA, et al.From cancer to immune-mediated diseases and tolerance induction: Lessons learned from immune oncology and classical anti-cancer treatment. Front Immunol2020;11:1423.
4.
BaldoBA. Immune-and non-immune-mediated adverse effects of monoclonal antibody therapy: A survey of 110 approved antibodies. Antibodies (Basel)2022;11(1):17.
5.
BlumSM, RouhaniSJ, SullivanRJ. Effects of immune‐related adverse events (irAEs) and their treatment on antitumor immune responses. Immunol Rev2023;318(1):167–178.
6.
van EijsMJ, VerheijdenRJ, van der WeesSA, et al.; UNICIT consortium. Toxicity-specific peripheral blood T and B cell dynamics in anti-PD-1 and combined immune checkpoint inhibition. Cancer Immunol Immunother2023;72(12):4049–4064.
7.
SimpsonRC, ShanahanER, ScolyerRA, et al.Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors. Nat Rev Clin Oncol2023;20(10):697–715.
8.
ZemekRM, AnagnostouV, Pires da SilvaI, et al.Exploiting temporal aspects of cancer immunotherapy. Nat Rev Cancer2024;24(7):480–497.
StricklerJH, HanksBA, KhasrawM. Tumor mutational burden as a predictor of immunotherapy response: Is more always better? Clin Cancer Res2021;27(5):1236–1241.
11.
WraithDC. The future of immunotherapy: A 20-year perspective. Front Immunol2017;8:1668; doi: 10.3389/fimmu.2017.01668
12.
MantoothSM, AbdouY, Saez-IbañezAR, et al.Intratumoral delivery of immunotherapy to treat breast cancer: Current development in clinical and preclinical studies. Front Immunol2024;15:1385484; doi: 10.3389/fimmu.2024.1385484
13.
ChakravartiD, WongWW. Synthetic biology in cell-based cancer immunotherapy. Trends Biotechnol2015;33(8):449–461; doi: 10.1016/j.tibtech.2015.05.001
14.
Rajeev-KumarG, PitrodaSP. Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization. Neoplasia2023;36:100867; doi: 10.1016/j.neo.2022.100867
15.
GuoCX, HuangX, XuJ, et al.Combined targeted therapy and immunotherapy for cancer treatment. World J Clin Cases2021;9(26):7643–7652; doi: 10.12998/wjcc.v9.i26.7643
16.
HodiFS, ChesneyJ, PavlickAC, et al.Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol2016;17(11):1558–1568.
17.
ZhaoY, GuoS, DengJ, et al.VEGF/VEGFR-targeted therapy and immunotherapy in non-small cell lung cancer: Targeting the tumor microenvironment. Int J Biol Sci2022;18(9):3845–3858; doi: 10.7150/ijbs.70958
18.
Da CunhaT, WuGY, VaziriH. Immunotherapy-induced hepatotoxicity: A review. J Clin Transl Hepatol2022;10(6):1194–1204; doi: 10.14218/JCTH.2022.00105
19.
MalikA, YousafMN, SamiullahS, et al.Overlapping hepatotoxicity and colitis associated with immune checkpoint inhibitors. J Community Hosp Intern Med Perspect2023;13(3):75–78; doi: 10.55729/2000-9666.1172
20.
WagesNA, SlingluffCLJr, PetroniGR. A phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma. Contemp Clin Trials2015;41:172–179; doi: 10.1016/j.cct.2015.01.016
21.
AshfaqUA, RiazM, YasmeenE, et al.Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment. Critical Reviews™ in Therapeutic Drug Carrier Systems2017;34(4).
22.
GerberDE. Targeted therapies: A new generation of cancer treatments. Am Fam Physician2008;77(3):311–319.
23.
SankarK, YeJC, LiZ, et al.The role of biomarkers in personalized immunotherapy. Biomark Res2022;10(1):32; doi: 10.1186/s40364-022-00378-0
24.
VatsavaiN, Kaur BhinderS, ShaikR, et al.Advances and challenges in cancer immunotherapy: Mechanisms, clinical applications, and future directions. Front Pharmacol2025;16:1602529.
25.
ColwellNA. Precision in progress: How biomarkers and targeted therapies are reshaping ovarian cancer care.ACCCBuzz Blog [Internet].2025 [cited 2025 Aug 24].
26.
RobbrechtDGJ, SalhiY, MartensJWM, et al.Novel molecular biomarkers to guide treatment decision-making in metastatic urothelial cancer-A patient cohort analysis. Eur Urol Oncol2026;9(1):7–11; doi: 10.1016/j.euo.2025.04.007
27.
RellingMV, HancockML, RiveraGK, et al.Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst1999;91(23):2001–2008.
28.
OnoderaR, ChibaS, NiheiS, et al.High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: A retrospective study. J Thorac Dis2023;15(8):4237–4247; doi: 10.21037/jtd-23-85
29.
GunjurA, ShaoY, RozdayT, et al.A gut microbial signature for combination immune checkpoint blockade across cancer types. Nat Med2024;30(3):797–809.
30.
AguilarH, López-RoldánB, Vilalta-LacarraA, et al.Liquid biopsy for monitoring minimal residual disease in localized and locally-advanced non-small cell lung cancer after radical-intent treatment. J Liq Biopsy2024;4:100145; doi: 10.1016/j.jlb.2024.100145
31.
BartolomucciA, NobregaM, FerrierT, et al.Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology. NPJ Precis Oncol2025;9(1):84.
32.
BandyopadhyayA, AlbashayrehA, ZeinaliN, et al.Using real-world electronic health record data to predict the development of 12 cancer-related symptoms in the context of multimorbidity. JAMIA Open2024;7(3):ooae082; doi: 10.1093/jamiaopen/ooae082
33.
YaoY, ZhouY, LiuL, et al.Its role in overcoming drug resistance. Front Mol Biosci2020;7:193; doi: 10.3389/fmolb.2020.00193
34.
FanD, CaoY, CaoM, et al.Nanomedicine in cancer therapy. Signal Transduct Target Ther2023;8(1):293.
35.
ShaikR, YashaswiB, AnjaliM, et al.Overcoming resistance mechanisms in cancer immunotherapy—novel approaches and combinations. Naunyn Schmiedebergs Arch Pharmacol2025;398(11):15209–15230.
36.
ChenN, BrachmannC, LiuX, et al.Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol2015;76(4):699–712.
37.
FuZ, LiS, HanS, et al.Antibody drug conjugate: The “biological missile” for targeted cancer therapy. Signal Transduct Target Ther2022;7(1):93.
38.
MuntasellA, CaboM, ServitjaS, et al.Interplay between natural killer cells and anti-HER2 antibodies: Perspectives for breast cancer immunotherapy. Front Immunol2017;8:1544.
39.
BharadVR, SheikhAA, KaleRH, et al.An updated look at implantable drug delivery systems. J Pharma Care Health Sys; 9:244.
40.
EbrahimniaM, AlaviS, VaeziH, et al.Exploring the vast potentials and probable limitations of novel and nanostructured implantable drug delivery systems for cancer treatment. Excli J2024;23:143–179; doi: 10.17179/excli2023-6747
41.
TalebianS, ForoughiJ, WadeSJ, et al.Biopolymers for antitumor implantable drug delivery systems: Recent advances and future outlook. Adv Mater2018;30(31):e1706665.
42.
ThomasRG, SurendranSP, JeongYY. Tumor microenvironment-stimuli responsive nanoparticles for anticancer therapy. Front Mol Biosci2020;7:610533; doi: 10.3389/fmolb.2020.610533
43.
JiaR, TengL, GaoL, et al.Advances in multiple stimuli-responsive drug-delivery systems for cancer therapy. Int J Nanomedicine2021;16:1525–1551.
44.
PerryMB, TaylorS, KhatoonB, et al.Examining the effectiveness of electronic patient-reported outcomes in people with cancer: Systematic review and meta-analysis. J Med Internet Res2024;26:e49089; doi: 10.2196/49089
45.
ChowR, DrkulecH, ImJHB, et al.The use of wearable devices in oncology patients: A systematic review. Oncologist2024;29(4) Pages:e419–e430.
46.
LeekhaS, TerrellCL, EdsonRS. General principles of antimicrobial therapy. Mayo Clin Proc2011;86No(2):156–167.
47.
KoinisF, NintosG, GeorgouliasV, et al.Therapeutic strategies for chemotherapy-induced neutropenia in patients with solid tumors. Expert Opin Pharmacother2015;16(10):1505–1519.
48.
DyGK, AdjeiAA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin2013;63(4):249–279.
49.
TralongoP, PescarenicoMG, SurboneA, et al.Physical needs of long-term cancer patients. Anticancer Res2017;37(9):4733–4746.
50.
IsakssonLJ, PepaM, ZaffaroniM, et al.Machine learning-based models for prediction of toxicity outcomes in radiotherapy. Front Oncol2020;10:790; doi: 10.3389/fonc.2020.00790
51.
OeiSP, BakkesTHGF, MischiM, et al.Artificial intelligence in clinical decision support and the prediction of adverse events. Front Digit Health2025;7:1403047; doi: 10.3389/fdgth.2025.1403047
52.
TremblayD, Joly-MischlichT, DufourA, et al.Telehomecare monitoring for patients receiving anticancer oral therapy: Protocol for a mixed methods evaluability study. JMIR Res Protoc2025;14:e63099; doi: 10.2196/63099
53.
LopezAM, LamK, ThotaR. Barriers and facilitators to telemedicine: Can you hear me now? Am Soc Clin Oncol Educ Book2021;41:25–36; doi: 10.1200/EDBK_320827
54.
RafiyathSM, RasulM, LeeB, et al.Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: A meta-analysis. Exp Hematol Oncol2012;1(1):10; doi: 10.1186/2162-3619-1-10
55.
MartinFJ. Pegylated liposomal doxorubicin: Scientific rationale and preclinical pharmacology. Oncol1997;11(10).
56.
PlattelWJ, BergamascoA, TrincheseF, et al.Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: A systematic review and meta-analysis. Leuk Lymphoma2021;62(14):3320–3332.
57.
LongR, ZuoH, TangG, et al.Antibody-drug conjugates in cancer therapy: Applications and future advances. Front Immunol2025;16:1516419; doi: 10.3389/fimmu.2025.1516419
58.
WillsB, BrahmerJR, NaidooJ. Treatment of complications from immune checkpoint inhibition in patients with lung cancer. Curr Treat Options Oncol2018;19(9):46; doi: 10.1007/s11864-018-0562-9
59.
MhandireDZ, GoeyAK. The value of pharmacogenetics to reduce drug-related toxicity in cancer patients. Mol Diagn Ther2022;26(2):137–151.
60.
SachaT. Imatinib in chronic myeloid leukemia: An overview. Mediterr J Hematol Infect Dis2014;6(1):e2014007; doi: 10.4084/MJHID.2014.007
61.
BraunTP, EideCA, DrukerBJ. Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell2020;37(4):530–542.
62.
OuX, MaQ, YinW, et al.CRISPR/Cas9 gene-editing in cancer immunotherapy: Promoting the present revolution in cancer therapy and exploring more. Front Cell Dev Biol2021;9:674467; doi: 10.3389/fcell.2021.674467
63.
ShaikR, GeraNE, SyedaFS, et al.An update on alkylating agents in breast cancer therapy. Cancer Biother Radiopharm2025;40(10):709–732.
64.
WinnZ. Equipping living cells with logic gates to fight cancer. MIT News2025
65.
KhanSH, ChoiY, VeenaM, et al.Advances in CAR T cell therapy: Antigen selection, modifications, and current trials for solid tumors. Front Immunol2024;15:1489827.
66.
TanDS, ThomasGV, GarrettMD, et al.Biomarker-driven early clinical trials in oncology: A paradigm shift in drug development. Cancer J2009;15(5):406–420.
67.
RobertsJA, NorrisR, PatersonDL, et al.Therapeutic drug monitoring of antimicrobials. Br J Clin Pharmacol2012;73(1):27–36.
68.
MansouriV, YazdanpanahN, RezaeiN. The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy. Int Rev Immunol2022;41(6):649–668.
69.
Abbas SoumayaKM. Immunotherapy toxicity-An overview(Doctoral dissertation).
70.
PreeditJ, HaydayM. Toxicity of traditional chemotherapy & targeted therapy.
71.
SmithBD, KaufmanMD, LearyCB, et al.Altiratinib inhibits tumor growth, invasion, angiogenesis, and microenvironment-mediated drug resistance via balanced inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther2015;14(9):2023–2034.
72.
EwerMS, O’ShaughnessyJA. Cardiac toxicity of trastuzumab-related regimens in HER2-overexpressing breast cancer. Clin Breast Cancer2007;7(8):600–607.
73.
AlharbiHM, AlqahtaniT, AlamriAH, et al.Nanotechnological synergy of mangiferin and curcumin in modulating PI3K/Akt/mTOR pathway: A novel front in ovarian cancer precision therapeutics. Front Pharmacol2023;14:1276209.
74.
CaldwellJ, GardnerI, SwalesN. An introduction to drug disposition: The basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol1995;23(2):102–114.
75.
PandyaB. Thiopurine S-Methyl Transferase Gene Polymorphism: Clinical Correlations. The University of Manchester (United Kingdom); 2010.
76.
BudăuLV, PopC, MogoșanC. Beyond the basics: Exploring pharmacokinetic interactions and safety in Tyrosine-kinase inhibitor oral therapy for solid tumors. Pharmaceuticals (Basel)2025;18(7):959.
77.
Al TameemiW, DaleTP, Al-JumailyRM, et al.Hypoxia-modified cancer cell metabolism. Front Cell Dev Biol2019;7:4.
78.
YazbeckV, AlesiE, MyersJ, et al.An overview of chemotoxicity and radiation toxicity in cancer therapy. Adv Cancer Res2022;155:1–27.
79.
HannaTP, KingWD, ThibodeauS, et al.Mortality due to cancer treatment delay: Systematic review and meta-analysis. BMJ2020;371:m4087.
80.
MaoY, ShangguanD, HuangQ, et al.Emerging artificial intelligence-driven precision therapies in tumor drug resistance: Recent advances, opportunities, and challenges. Mol Cancer2025;24(1):123.
81.
CrawfordS. Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapy. Front Pharmacol2013;4:68.
82.
MarquesL, CostaB, PereiraM, et al.Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics2024;16(3):332.
83.
EzikeTC, OkpalaUS, OnojaUL, et al.Advances in drug delivery systems, challenges and future directions. Heliyon2023;9(6):e17488.
84.
DosioF, BrusaP, CrosassoP, et al.Preparation, characterization and properties in vitro and in vivo of a paclitaxel–albumin conjugate. Journal of Controlled Release1997;47(3):293–304.
85.
Abdollahpour‐AlitappehM, LotfiniaM, GharibiT, et al.Antibody–drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes. Journal Cellular Physiology2019;234(5):5628–5642.
86.
LeeK, SilvaEA, MooneyDJ. Growth factor delivery-based tissue engineering: General approaches and a review of recent developments. J R Soc Interface2011;8(55):153–170.
87.
BinkhorstL, MathijssenRH, JagerA, et al.Individualization of tamoxifen therapy: Much more than just CYP2D6 genotyping. Cancer Treat Rev2015;41(3):289–299.
88.
KlempnerSJ, FabrizioD, BaneS, et al.Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors: A review of current evidence. The Oncologist2020;25(1):e147-59–e159.
89.
LieschkeGJ, BurgessAW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. N Engl J Med1992;327(2):99–106.
90.
RojasC, RajeM, TsukamotoT, et al.Molecular mechanisms of 5-HT3 and NK1 receptor antagonists in prevention of emesis. Eur J Pharmacol2014;722:26–37.
91.
AbrahmJ, AbrahmJL, MomentA, et al.A physician’s guide to pain and symptom management in cancer patients. JHU Press; 2014.
92.
BielinskiSJ, OlsonJE, PathakJ, et al.Preemptive genotyping for personalized medicine: Design of the right drug, right dose, right time—using genomic data to individualize treatment protocol. Mayo Clin Proc2014;89(1):25–33.
93.
SmitaP, NarayanPA, JK, et al.Therapeutic drug monitoring for cytotoxic anticancer drugs: Principles and evidence-based practices. Front Oncol2022;12:1015200.
94.
GatenbyRA, SilvaAS, GilliesRJ, et al.Adaptive therapy. Cancer Res2009;69(11):4894–4903.
95.
DanceyJE, ChenHX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov2006;5(8):649–659.
96.
LahiriA, MajiA, PotdarPD, et al.Lung cancer immunotherapy: Progress, pitfalls, and promises. Mol Cancer2023;22(1):40.
97.
KroschinskyF, StölzelF, von BoninS, et al.; Intensive Care in Hematological and Oncological Patients (iCHOP) Collaborative Group. New drugs, new toxicities: Severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care2017;21(1):89.
98.
JunttilaMR, De SauvageFJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature2013;501(7467):346–354.
99.
GaoW, ChanJM, FarokhzadOC. pH-responsive nanoparticles for drug delivery. Mol Pharm2010;7(6):1913–1920.
100.
BejaranoL, JordāoMJ, JoyceJA. Therapeutic targeting of the tumor microenvironment. Cancer Discov2021;11(4):933–959.
101.
SoleymaninejadianE. Comprehensive insights into HPV 16 immunity: From T cell activation and proliferation to vaccine design and drug discovery.
102.
SharmaP, AllisonJP. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell2015;161(2):205–214.
103.
KotchC, BarrettD, TeacheyDT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol2019;15(8):813–822.
104.
NgiamKY, KhorW. Significant data and machine learning algorithms for health-care delivery. Lancet Oncol2019;20(5):e262-73–e273.
105.
KyriacosU, JelsmaJ, JordanS. Monitoring vital signs using early warning scoring systems: A review of the literature. J Nurs Manag2011;19(3):311–330.
106.
AdepojuAH, Austin-GabrielBL, HamzaOL, et al.Advancing monitoring and alert systems: A proactive approach to improving reliability in complex data ecosystems. IRE Journals2022;5(11):281–282.
107.
KrzyszczykP, AcevedoA, DavidoffEJ, et al.The growing role of precision and personalized medicine for cancer treatment. Technology (Singap World Sci)2018;6(3–4):79–100.
108.
StrzelecM, DetkaJ, MieszczakP, et al.Immunomodulation—a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front Immunol2023;14:1127704.
109.
RasoolS, AliM, ShahrozHM, et al.Innovations in AI-powered healthcare: Transforming cancer treatment with innovative methods. BULLET: Jurnal Multidisiplin Ilmu2024;3(1):118–128.
110.
ModingEJ, KastanMB, KirschDG. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat Rev Drug Discov2013;12(7):526–542.
111.
MathijssenRH, SparreboomA, VerweijJ. Determining the optimal dose in the development of anticancer agents. Nat Rev Clin Oncol2014;11(5):272–281.
112.
GustafsonDL, PageRL. Cancer chemotherapy. Small Animal Clinical Oncology2012;5:157–179.
PatsalosPN, BerryDJ, BourgeoisBF, et al.Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia2008;49(7):1239–1276.
115.
NiuG, ChenX. Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy. Curr Drug Targets2010;11(8):1000–1017.
RosenbaumSE. editor. Basic pharmacokinetics and pharmacodynamics: An integrated textbook and computer simulations. John Wiley & Sons; 2016.
118.
SignificantanzoliL, CuferT, BruningP, et al.Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial. Journal of Clinical Oncology2002;20(14):3114–3121.
119.
BansalD, DavidsonA, SupriyadiE, et al.SIOP PODC adapted risk stratification and treatment guidelines: Recommendations for acute myeloid leukemia in resource‐limited settings. Pediatr Blood Cancer2023;70(11):e28087.
120.
KerbelRS, KamenBA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer2004;4(6):423–436.
121.
HanahanD, BergersG, BergslandE. Less is more, regularly: Metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest2000;105(8):1045–1047.
122.
Ramos-CasalsM, BrahmerJR, CallahanMK, et al.Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers2020;6(1):38.
123.
LiuFS. Mechanisms of chemotherapeutic drug resistance in cancer therapy—A quick review. Taiwan J Obstet Gynecol2009;48(3):239–244.
124.
MormontMC, LeviF. Cancer chronotherapy: Principles, applications, and perspectives. Cancer: Interdisciplinary International Journal of the American Cancer Society2003;97(1):155–169.
125.
VannemanM, DranoffG. Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer2012;12(4):237–251.
126.
Ruiz-GarciaA, BaverelP, BottinoD, et al.A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development. J Pharmacokinet Pharmacodyn2023;50(3):147–172.
127.
GrayR, BradleyR, BraybrookeJ, et al.Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet2019;393(10179):1440–1452.
128.
CaliffRM, PetersonED, GibbonsRJ, et al.; American Heart Association. Integrating quality into the cycle of therapeutic development. J Am Coll Cardiol2002;40(11):1895–1901.
129.
La ThangueNB, KerrDJ. Predictive biomarkers: A paradigm shift towards personalized cancer medicine. Nat Rev Clin Oncol2011;8(10):587–596.
130.
RossariF, MinutoloF, OrciuoloE. Past, present, and future of Bcr-Abl inhibitors: From chemical development to clinical efficacy. J Hematol Oncol2018;11(1):84.
PecorinoL. Molecular biology of cancer: mechanisms, targets, and therapeutics. Oxford university press; 2021.
133.
LinJJ, ChoudhuryNJ, YodaS, et al.Spectrum of mechanisms of resistance to crizotinib and lorlatinib in ROS1 fusion–positive lung cancer. Clin Cancer Res2021;27(10):2899–2909.
134.
MigaliC. Site-and histology-independent indications of medicinal products in oncology.
135.
SerratìS, De SummaS, PilatoB, et al.Next-generation sequencing: Advances and applications in cancer diagnosis. Onco Targets Ther2016;9:7355–7365.
136.
ZhangX, WuT, CaiX, et al.Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities. Front Immunol2022;13:795972.
137.
ShaikR, MalikMS, BasavarajuS, et al.Cellular and molecular aspects of drug resistance in cancers. Daru2024;33(1):4.
138.
JianY, LiuY, XieJ. transformed to small cell lung. Advancements and cutting-edge approaches to counteract the inefficacy of immune checkpoint inhibitor therapies in lung cancer. 2025 Apr 29.
139.
EspositoA, CriscitielloC, LocatelliM, et al.Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. Pharmacol Ther2016;157:120–124.
140.
YoonSJ, LeeCB, ChaeSU, et al.The comprehensive “OMICS” approach from metabolomics to advanced omics for development of immune checkpoint inhibitors: Potential strategies for next generation of cancer immunotherapy. Int J Mol Sci2021;22(13):6932.
141.
VamathevanJ, ClarkD, CzodrowskiP, et al.Applications of machine learning in drug discovery and development. Nat Rev Drug Discov2019;18(6):463–477.
142.
DrukerBJ, GuilhotF, O’BrienSG, et al.; IRIS Investigators. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med2006;355(23):2408–2417.
143.
LongGV, StroyakovskiyD, GogasH, et al.Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med2014;371(20):1877–1888.
144.
O’HareAM, RodriguezRA, BowlingCB. Caring for patients with kidney disease: Shifting the paradigm from evidence-based medicine to patient-centered care. Nephrology Dialysis Transplantation2016;31(3):368–375.
145.
SrivastavaR. Applications of artificial intelligence multiomics in precision oncology. J Cancer Res Clin Oncol2023;149(1):503–510.
146.
MoradG, HelminkBA, SharmaP, et al.Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell2021;184(21):5309–5337.
147.
ShaikR, RoyyalaSA, InapanuriB, et al.Tumor infiltration therapy: From FDA approval to next-generation approaches. Clin Exp Med2025;25(1):254.
148.
DuffyMJ, O’DonovanN, CrownJ. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat Rev2011;37(2):151–159.
149.
SmithM, DaiA, GhilardiG, et al.Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med2022;28(4):713–723.
SchaafMB, GargAD, AgostinisP. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis2018;9(2):115.
152.
LopezJS, BanerjiU. Combine and conquer: Challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol2017;14(1):57–66.
153.
RileyRS, JuneCH, LangerR, et al.Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov2019;18(3):175–196.
154.
ShaikR, ChittepuSM, TarapatlaM, et al.Chemoimmunotherapy synergism: Mechanisms and clinical applications. Naunyn Schmiedebergs Arch Pharmacol2025;398(9):11761–11782.
155.
NaidooJ, ZhangJ, LipsonEJ, et al.A multidisciplinary toxicity team for cancer immunotherapy–related adverse events. J Natl Compr Canc Netw2019;17(6):712–720.
156.
AlamriAM, AssiriAA, KhanB, et al.Next-generation oncology: Integrative therapeutic frontiers at the crossroads of precision genomics, immuno-engineering, and tumor microenvironment modulation. Med Oncol2025;42(11):482–420.
157.
MorgantiS, TarantinoP, FerraroE, et al.Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. Crit Rev Oncol Hematol2019;133:171–182.
158.
ChennamadhavuniA, AbushahinL, JinN, et al.Risk factors and biomarkers for immune-related adverse events: A practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors. Front Immunol2022;13:779691.
159.
ElhaddadM, HamamS. AI-driven clinical decision support systems: An ongoing pursuit of potential. Cureus2024;16(4):e57728.
160.
MokhosoevIM, AstakhovDV, TerentievAA, et al.Human cytochrome P450 cancer-related metabolic activities and gene polymorphisms: A Review. Cells2024;13(23):1958.
161.
GaleD, HeiderK, Ruiz-ValdepenasA, et al.Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer. Ann Oncol2022;33(5):500–510.
162.
HaringE, BuescherJM, ApostolovaP. Metabolism in hematology: Technological advances open new perspectives on disease biology and treatment. Hemasphere2025;9(5):e70134.
163.
ManzariMT, ShamayY, KiguchiH, et al.Targeted drug delivery strategies for precision medicines. Nat Rev Mater2021;6(4):351–370.
164.
TahoverE, PatilYP, GabizonAA. Emerging delivery systems to reduce doxorubicin cardiotoxicity and improve therapeutic index: Focus on liposomes. Anticancer Drugs2015;26(3):241–258.
165.
BarokM, JoensuuH, IsolaJ. Trastuzumab emtansine: Mechanisms of action and drug resistance. Breast Cancer Res2014;16(2):209.
166.
HaiderK, RahamanS, YarMS, et al.Tubulin inhibitors as novel anticancer agents: An overview on patents (2013-2018). Expert Opin Ther Pat2019;29(8):623–641.
167.
LiaoZ, LiuT, YaoZ, et al.Harnessing stimuli‐responsive biomaterials for advanced biomedical applications. Exploration (Beijing)2025;5(1):20230133.
168.
YakkalaPA, RahamanS, SoukyaPL, et al.An update on the development on tubulin inhibitors for the treatment of solid tumors. Expert Opin Ther Targets2024;28(3):193–220.
169.
MitchellMJ, JainRK, LangerR. Engineering and physical sciences in oncology: Challenges and opportunities. Nat Rev Cancer2017;17(11):659–675.
BennetotA, Zia Ur RehmanR, RomijndersR, et al.Characterizing patient-reported fatigue using electronic diaries in neurodegenerative and immune-mediated inflammatory diseases: Observational Study. JMIR Form Res2025;9:e65879.
172.
ClaytonTA, LindonJC, CloarecO, et al.Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature2006;440(7087):1073–1077.
173.
DaleDC. Colony-stimulating factors for the management of neutropenia in cancer patients. Drugs2002;62(Suppl 1):1–15.
174.
RudroffT. Pharmacological and Non-pharmacological Interventions. In Long COVID Fatigue: Clinical Sciences, Artificial Intelligence and the Future of Brain Health2025 (pp. 135–154). Cham: Springer Nature Switzerland.
175.
SuttonRT, PincockD, BaumgartDC, et al.An overview of clinical decision support systems: Benefits, risks, and strategies for success. NPJ Digit Med2020;3(1):17.
176.
IorfinoF, PiperSE, ProdanA, et al.Using digital technologies to facilitate care coordination between youth mental health services: A guide for implementation. Front Health Serv2021;1:745456.
177.
DugganST, KeatingGM. Pegylated liposomal doxorubicin: A review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi’s sarcoma. Drugs2011;71(18):2531–2558.
178.
VargasonAM, AnselmoAC, MitragotriS. The evolution of commercial drug delivery technologies. Nat Biomed Eng2021;5(9):951–967.
179.
WilsonWH, BryantG, BatesS, et al.EPOCH chemotherapy: Toxicity and efficacy in relapsed and refractory non-Hodgkin’s lymphoma. J Clin Oncol1993;11(8):1573–1582.
180.
AddeoA, FriedlaenderA, BannaGL, et al.TMB or not TMB as a biomarker: That is the question. Crit Rev Oncol Hematol2021;163:103374.
181.
FranczykB, RyszJ, Gluba-BrzózkaA. Pharmacogenetics of drugs used in the treatment of cancers. Genes (Basel)2022;13(2):311.
182.
PrajapatiRN, BhushanB, SinghK, et al.Recent advances in pharmaceutical design: Unleashing the potential of novel therapeutics. Curr Pharm Biotechnol2024;25(16):2060–2077.
183.
WangSW, GaoC, ZhengYM, et al.Current applications and future perspective of CRISPR/Cas9 gene editing in cancer. Mol Cancer2022;21(1):57.
184.
PatilC, PriyankaR, HarshithaBM, et al.Advanced nanotheranostic approaches for targeted glioblastoma treatment: A synergistic fusion of CRISPR-Cas gene editing, AI-driven tumor profiling, and BBB-modulation. Med Oncol2025;42(9):1–32.
185.
YadagiriU, ShaikR, KolureR, et al.Immunotherapeutics in Clinical Trials for Cervical Cancer. Cancer Biother Radiopharm2025;40(6):377–388.
186.
ZhongX, D’AntonaAM. Recent advances in the molecular design and applications of multispecific biotherapeutics. Antibodies (Basel)2021;10(2):13.
187.
WagnerEH, AustinBT, Von KorffM. Organizing care for patients with chronic illness. Milbank Q1996;74(4):511–544.
188.
LangerAS. Side effects, quality-of-life issues, and trade-offs: The patient perspective. J Natl Cancer Inst Monogr2001;2001(30):125–129.
189.
DuttonDB. Worse than the disease: Pitfalls of medical progress. Cambridge University Press; 1992 May 29.
190.
YuX, LuanS, LeiS, et al.Deep learning for fast denoising filtering in ultrasound localization microscopy. Phys Med Biol2023;68(20):205002.
191.
JiangZ, ChenZ, XuY, et al.Low‐frequency ultrasound sensitive Piezo1 channels regulate keloid‐related characteristics of fibroblasts. Advanced Science2024;11(14):2305489.
192.
YangJ, WangG, XiaoX, et al.Explainable ensemble learning method for OCT detection with transfer learning. PLoS One2024;19(3):e0296175.
193.
WangZB, ZhangX, FangC, et al.Immunotherapy and the ovarian cancer microenvironment: Exploring potential strategies for enhanced treatment efficacy. Immunology2024;173(1):14–32.
194.
YangJ, YaoYL, LvXY, et al.The safety and efficacy of inactivated COVID-19 vaccination in couples undergoing assisted reproductive technology: A prospective cohort study. Vaccine2025;45:126635.
